Clinical study of yiqi huoxue recipe in the treatment of liver fibrosis of chronic viral hepatitis

Objective: To clarify the clinical efficacy of Yiqi Huoxue recipe in the treatment of liver fibrosis of chronic viral hepatitis. Methods: An open, positive-drug, parallel-controlled study method was applied. A total of 207 cases of liver fibrosis with chronic hepatitis B and C diagnosed with liver biopsy and transient elastography were selected. According to the principle of syndrome differentiation in traditional Chinese medicine, self-made Yiqi Huoxue recipe (n = 127) and Fuzheng Huayu capsule (n = 80) were used for the treatment course of 24-48 weeks. Change score of TCM symptom, liver biochemistry, liver stiffness measurement (LSM), and noninvasive liver fibrosis index [aspartate transaminase to platelet ratio index (APRI), and fibrosis-4 score (FIB-4)] were compared between the two groups to evaluate the therapeutic effect of Yiqi Huoxue recipe on liver fibrosis. Results: Yiqi Huoxue recipe group and Fuzheng Huayu capsule group baseline LSM, APRI and FIB-4 was compared, and there was no statistically significant difference between them (P > 0.05). Yiqi Huoxue recipe and Fuzheng Huayu capsule received patients had improved symptom scores to a certain extent. Hepatic facies, discomfort over liver area, and soreness and weakness of waist and knees (P < 0.05) was significantly improved in Yiqi Huoxue recipe than Fuzheng Huayu capsule. Liver biochemical indicators (ALT, AST, GGT, ALP) had gradually relapsed with the extension of treatment duration and the normalization rate between the two groups after 24 to 48 weeks had reached 100% vs. 100%, 100% vs. 93.8%, 96.8% vs. 92.3% and 87.5% vs. 81.8%. After 12 weeks of treatment, APRI values ​​of both groups had significantly reduced, and after 48 weeks of treatment, LSM values of both groups had significantly improved. Moreover, Yiqi Huoxue recipe FIB-4 score was significantly improved after 48 weeks of treatment, and the difference was statistically significant compared to Fuzheng Huayu capsule group (P < 0.05). After treatment, LSM, APRI, and FIB-4 total effectiveness in the two groups were 80.0% vs. 63.6%, P = 0.046; 68.4% vs. 52.0%, P = 0.052; 68.4% vs. 62.0%, P = 0.437, respectively. LSM total effectiveness was significantly higher in Yiqi Huoxue recipe treated group than Fuzheng Huayu capsule group. Conclusion: Traditional Chinese medicine Yiqi Huoxue decoction can be used as an optimal treatment for liver fibrosis of chronic viral hepatitis.

Medienart:

E-Artikel

Erscheinungsjahr:

2020

Erschienen:

2020

Enthalten in:

Zur Gesamtaufnahme - volume:28

Enthalten in:

Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology - 28(2020), 5 vom: 20. Mai, Seite 403-409

Sprache:

Chinesisch

Beteiligte Personen:

Cui, L Y [VerfasserIn]
Zhang, X X [VerfasserIn]
Cui, P [VerfasserIn]
Li, W C [VerfasserIn]
Zhang, Y G [VerfasserIn]
Wang, R Q [VerfasserIn]
Zhao, S X [VerfasserIn]
Ren, W G [VerfasserIn]
Kong, L L [VerfasserIn]
Han, F [VerfasserIn]
Yuan, X W [VerfasserIn]
Liu, L D [VerfasserIn]
Zhang, Y [VerfasserIn]
Zhang, Q S [VerfasserIn]
Kong, L [VerfasserIn]
Nan, Y M [VerfasserIn]

Links:

Volltext

Themen:

Aspartate Aminotransferases
Chronic hepatitis
Drugs, Chinese Herbal
EC 2.6.1.1
Fuzheng Huayu capsules
Journal Article
Liver fibrosis
Traditional Chinese medicine
Yiqi Huoxue

Anmerkungen:

Date Completed 09.11.2020

Date Revised 09.11.2020

published: Print

Citation Status MEDLINE

doi:

10.3760/cma.j.cn501113-20190905-00325

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM311151760